Dr. Benedict Law’s research at Weill Cornell Medicine (WCM) has focused on new drug delivery strategies such as the use of smart nanomaterials and peptides to promote drug delivery, tumoral uptake and tissue penetration for cancer treatments. His research group routinely applies multimodal imaging techniques (positron emission tomography/computed tomography (PET/CT)/fluorescence) to study pharmacokinetics and biodistribution of chemotherapy.
Associated Lab Members
Dr. Benedict Law is an associate professor of pharmacology in radiology, Weill Cornell Medicine (WCM). He was trained as a hospital pharmacist in the United Kingdom prior to obtaining his Ph.D. at the University of Manchester. After he completed his postdoctoral training at Massachusetts General Hospital, he was recruited as a faculty member at North Dakota State University. In 2013, he joined the Molecular Imaging Innovations Institute (MI3) at WCM.
To improve treatment outcome, multiple drugs of distinctive mechanisms but complementary anticancer activities are often used to enhance antitumor efficacy and minimize risk of acquiring drug resistance. Specifically, the Law lab investigates the synergistic effects of drug combinations, with the aim of developing new therapeutic strategies,...
Most bladder cancer (BC) patients are diagnosed early. The standard treatment is to surgically remove the tumors, followed by intravesical immunotherapy (bacillus Calmette-Guerin) or intravesical chemotherapy (ITC) to eradicate any residual cancer cells. The current ITC are limited due to incomplete treatment, poor patient compliance, and...
Of all pediatric cancers, diffuse intrinsic pontine glioma (DIPG) is the most aggressive. Focal radiotherapy only prolongs patient survival for a few months. Chemotherapy does not improve patient survival as DIPG is intrinsically resistant to most chemotherapeutics. Furthermore, our brains naturally prevent most drugs from reaching the...
Drawbacks of nanoparticles are: poor tissue extravasation, incomplete drug release, and off-targeted delivery to the reticuloendothelial system and organs. The Law lab developed a new nanofiber platform (NFP) displaying a unique dimension (0.5 x 5 x 100 nm) different from other nanoparticles. The NFP has an excellent tumor-targeting...
